Literature DB >> 16522582

Estimating the cost of new drug development: is it really 802 million dollars?

Christopher P Adams1, Van V Brantner.   

Abstract

This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be 868 million dollars. However, our estimates vary from around 500 million dollars to more than 2,000 million dollars, depending on the therapy or the developing firm.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522582     DOI: 10.1377/hlthaff.25.2.420

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  182 in total

Review 1.  Ingestion-controlling network: what's language got to do with it?

Authors:  Michael Myslobodsky; Richard Coppola
Journal:  Rev Neurosci       Date:  2010       Impact factor: 4.353

2.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

3.  The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

Authors:  Amanda G Paulovich; Jeffrey R Whiteaker; Andrew N Hoofnagle; Pei Wang
Journal:  Proteomics Clin Appl       Date:  2008-10-01       Impact factor: 3.494

Review 4.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

5.  FDA approval for use of medications in pregnancy: an uphill battle.

Authors:  Errol R Norwitz; James A Greenberg
Journal:  Rev Obstet Gynecol       Date:  2011

6.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

7.  Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.

Authors:  Tudor I Oprea; Sonny Kim Nielsen; Oleg Ursu; Jeremy J Yang; Olivier Taboureau; Stephen L Mathias; Lrene Kouskoumvekaki; Larry A Sklar; Cristian G Bologa
Journal:  Mol Inform       Date:  2011-03-14       Impact factor: 3.353

8.  Study of drug function based on similarity of pathway fingerprint.

Authors:  Hao Ye; Kailin Tang; Linlin Yang; Zhiwei Cao; Yixue Li
Journal:  Protein Cell       Date:  2012-03-17       Impact factor: 14.870

9.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

10.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.